Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 + oxaliplatin + nanoliposomal irinotecan + sintilimab vs S-1 + oxaliplatin + sintilimab in first-line advanced gastric cancer
ChiCTR2400085893Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tegafur, oxaliplatin, nanoliposomal irinotecan and sintilimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective Response Rate. Started Jun 2024; status: recruiting.
02
Drugs
tegafuroxaliplatinnanoliposomal irinotecansintilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400085893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085893.